Average Glucose Estimation Using Red Blood Cell Lifespan
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for estimating average glucose levels from glycated hemoglobin (HbA1c) are inaccurate due to inter-individual variations, leading to misinformed treatment decisions in diabetes management.
Innovation Solution
A subject-specific relationship is established between red blood cell age or lifespan and HbA1c and blood glucose concentration using continuous glucose monitoring data, allowing for accurate estimation of average glucose levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard HbA1c-based average glucose estimation methods are used, then treatment decisions can be made, but the accuracy of glucose estimation deteriorates due to inter-individual variations
Solution Approach 1:
The patent segments the population into individuals with different red blood cell lifespans and establishes separate estimation equations for each segment. This allows the system to account for inter-individual variations by selecting the appropriate segment-specific equation based on the patient's RBC lifespan characteristics, thereby improving measurement precision without sacrificing adaptability.
Solution Approach 2:
The patent changes the estimation approach by incorporating red blood cell lifespan as a key parameter. Instead of using a single universal HbA1c-to-glucose conversion, the system adjusts the estimation by considering variations in RBC lifespan parameters across different individuals, which directly addresses the accuracy deterioration caused by inter-individual variations.
2Measurement precision
If continuous glucose monitoring is performed, then accurate real-time glucose data is obtained, but the invasiveness and complexity of the system increases
Solution Approach 1:
The patent creates a mathematical model (a virtual copy) that replicates the function of continuous glucose monitoring by using HbA1c levels and red blood cell lifespan parameters to estimate average glucose. This copying approach provides accurate glucose information without requiring actual continuous monitoring hardware, thereby reducing device complexity and invasiveness while maintaining measurement precision.
3Ease of operation
If episodic blood glucose measurements are taken, then treatment decisions can be made, but the accuracy of average glucose capture deteriorates
Solution Approach 1:
The patent performs preliminary action by measuring HbA1c levels and determining red blood cell lifespan parameters in advance. These preliminary measurements enable the system to calculate and estimate average glucose levels without requiring frequent episodic blood glucose tests, thus maintaining ease of operation while improving the accuracy of average glucose capture through the established estimation equations.
Data Source
AI summary
A method includes estimating a value of a parameter indicative of an age or lifespan of a population of red blood cells of a subject, estimating a value of average glucose (AG) of the subject based on (i) the value of the parameter and (ii) a value indicative of an amount of glycated hemoglobin (HbA1c) of the subject, and providing information for treatment or diagnosis of a hyperglycemia condition of the subject based on the estimated value of AG.